GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine CongressGlobeNewsWire • 04/05/23
GeoVax to Participate at the World Vaccine Congress with Multiple PresentationsGlobeNewsWire • 03/30/23
GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine CongressGlobeNewsWire • 03/15/23
GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate UpdateGlobeNewsWire • 03/09/23
GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic InfectionsGlobeNewsWire • 02/27/23
GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical TrialGlobeNewsWire • 02/15/23
GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based VaccinesGlobeNewsWire • 02/08/23
GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck CancersGlobeNewsWire • 02/07/23
GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023GlobeNewsWire • 01/04/23
Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVaxGlobeNewsWire • 12/20/22
GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022GlobeNewsWire • 11/28/22
GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/09/22
GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022GlobeNewsWire • 10/26/22